StockStory.org on MSN
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks with high potential. BioMarin Pharmaceutical Inc ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
10d
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks
BioMarin has both a solid revenue portfolio of several products and a promising pipeline. Click here to see why BMRN stock is ...
In the last three months, 8 analysts have published ratings on Biomarin Pharmaceutical (NASDAQ:BMRN), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the ...
BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for rare ...
BioMarin’s Q4 adjusted EPS rose to $0.92, surpassing the $0.53 consensus. 2025 sales guidance set at $3.1 billion-$3.2 billion, with EPS expected at $4.20-$4.40. Get the data-driven signals to profit ...
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares ...
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected ...
We came across a bullish thesis on BioMarin Pharmaceutical Inc. on Value investing subreddit by ProudlyRegarded. In this article, we will summarize the bulls’ thesis on BMRN. BioMarin Pharmaceutical ...
BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results on Wednesday, February 19th. The company reported earnings of $0.92 per share, beating estimates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback